Iovance Biotherapeutics
IOVA · Nasdaq · United States
Share price · IOVA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IOVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Oct 2026-35.4%
- 29 Sep 2026+31.5%
- 20 Aug 2026+12.5%
Nothing announced by IOVA that day or the session before.
- 6 Aug 2026+43.1%
- 31 Jul 2026-13.2%
- 15 Jul 2026+20.6%
Nothing announced by IOVA that day or the session before.
- 4 Jun 2026+15.6%
- 22 May 2026+11.1%
- 9 Apr 2026+15.6%
Nothing announced by IOVA that day or the session before.
- 12 Mar 2026-15.9%
Nothing announced by IOVA that day or the session before.
Share of unusual movement by asset
For each asset, the share of IOVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
aldesleukin(Proleukin) | Approved | Interleukin-2 receptor (IL-2R)Other | Renal Cell CarcinomaMelanoma |
lifileucel(Amtagvi) | Approved | Tumor-infiltrating lymphocytes (polyclonal tumor antigens)Cell therapy | Melanoma |
| Phase 2 | No discrete molecular targetCell therapy | Non-Small Cell Lung Cancer | |
| Phase 2 | Tumor-infiltrating lymphocytes (TIL) | Non-Small Cell Lung Cancer | |
| Phase 1/2 | PD-1Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
September 2027 (1)
December 2027 (1)
What to watch
2028 (2)
2030 (1)
2032 (1)
June 2032 (1)
What to watch
2033 (1)
September 2033 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $121M | $49M | $64M+ $318M short-term inv. | $22M-$4.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $99M | $59M | $117M+ $187M short-term inv. | $47M-$61M operating cash flow | report ↗ |
| 2026-Q1 | $71M | $62M | $197M+ $117M short-term inv. | $79M-$72M operating cash flow | report ↗ |
| 2025-Q3 | $67M | $75M | $164M+ $143M short-term inv. | $91M-$79M operating cash flow | report ↗ |
| 2025-Q2 | $60M | $79M | $138M+ $169M short-term inv. | $112M-$67M operating cash flow | report ↗ |
| 2025-Q1 | $49M | $77M | $178M+ $188M short-term inv. | $116M-$104M operating cash flow | report ↗ |
| 2024-Q3 | $59M | $68M | $171M+ $233M short-term inv. | $84M-$59M operating cash flow | report ↗ |
| 2024-Q2 | $31M | $62M | $235M+ $184M short-term inv. | $97M-$98M operating cash flow | report ↗ |
| 2024-Q1 | $0.7M | $80M | $141M+ $222M short-term inv. | $113M-$122M operating cash flow | report ↗ |
| 2023-Q3 | $0.5M | $88M | $334M+ $94M short-term inv. | $114M-$84M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $86M | $296M+ $21M short-term inv. | $107M-$94M operating cash flow | report ↗ |
| 2023-Q1 | — | $83M | $550M+ $83M short-term inv. | $107M-$100M operating cash flow | report ↗ |
| 2022-Q3 | — | $73M | $125M+ $242M short-term inv. | $100M-$64M operating cash flow | report ↗ |
| 2022-Q2 | — | $73M | $115M+ $316M short-term inv. | $99M-$78M operating cash flow | report ↗ |
| 2022-Q1 | — | $68M | $98M+ $390M short-term inv. | $92M-$74M operating cash flow | report ↗ |
| 2021-Q3 | — | $65M | $65M+ $518M short-term inv. | $86M-$58M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $264M | $300M | $163M+ $134M short-term inv. | $98M-$302M operating cash flow | report ↗ |
Iovance reported full-year 2025 revenue of $263.502M, up 60.6% YoY, and R&D spend of $300.27M, up 8.7% YoY. The company ended the year with a cash position of approximately $303M and reported a net loss of $390.978M.
The company achieved its FY25 revenue guidance of $250–300M and expects its cash position to fund operations into the third quarter of 2027. Key business updates included FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer, positive interim data in that setting, and a planned registrational trial in previously treated advanced sarcomas. Amtagvi's five-year C-144-01 analysis and real-world response data, along with ongoing global regulatory submissions, were also highlighted.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $164M | $276M | $116M+ $208M short-term inv. | $93M-$353M operating cash flow | report ↗ |
| 2023-FY | $1.2M | $333M | $115M+ $165M short-term inv. | $111M-$362M operating cash flow | report ↗ |
| 2022-FY | — | $295M | $238M+ $240M short-term inv. | $99M-$293M operating cash flow | report ↗ |
| 2021-FY | — | $259M | $84M+ $426M short-term inv. | $86M-$228M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | Vogt Frederick G · director, Interim CEO & General Counsel | Option exercise | 200,000 | $7.55 | $1.5M | Form 4 |
| 2026-11-11 | Vogt Frederick G · director, Interim CEO & General Counsel | Tax withholding | 191,303 | $8.09 | $1.5M | Form 4 |
| 2026-11-11 | Vogt Frederick G · director, Interim CEO & General Counsel | Option exercise (derivative) | 200,000 | — | — | Form 4 |
| 2026-11-10 | Kirby Daniel Gordon · Chief Commercial Officer | Option exercise | 10,000 | — | — | Form 4 |
| 2026-11-10 | Kirby Daniel Gordon · Chief Commercial Officer | Tax withholding | 3,935 | $8.08 | $32K | Form 4 |
| 2026-11-10 | Kirby Daniel Gordon · Chief Commercial Officer | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-11-06 | Roche Corleen M. · Chief Financial Officer | Option exercise | 12,500 | — | — | Form 4 |
| 2026-11-06 | Roche Corleen M. · Chief Financial Officer | Tax withholding | 5,311 | $8.04 | $43K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 283 reporting institutions held 269.0M shares ($910.0M, 58.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 31,080,505 | $109.1M |
| 2 | MHR FUND MANAGEMENT LLC | 28,967,103 | $101.7M |
| 3 | STATE STREET CORP | 17,448,108 | $61.2M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 16,617,737 | $58.3M |
| 5 | TWO SIGMA INVESTMENTS, LP | 13,687,433 | $48.0M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11,700,844 | $41.1M |
| 7 | MILLENNIUM MANAGEMENT LLC | 9,414,292 | $33.0M |
| 8 | GOLDMAN SACHS GROUP INC | 8,760,060 | $30.7M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 8,572,598 | $30.1M |
| 10 | Invenomic Capital Management LP | 8,495,551 | $29.8M |
| 11 | BANK OF AMERICA CORP /DE/ | 8,490,119 | $29.8M |
| 12 | D. E. Shaw & Co., Inc. | 8,016,353 | $28.1M |
| 13 | Palo Alto Investors LP | 6,349,563 | $22.3M |
| 14 | MORGAN STANLEY | 6,201,282 | $21.8M |
| 15 | JANE STREET GROUP, LLC | 4,173,886 | $14.7M |